Plain-English translation of NCT06769425 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new oral medication called HS-10502 combined with other standard cancer treatments in people with advanced solid tumors. Researchers want to find the right dose of this medication and understand how safe it is when paired with drugs like chemotherapy, hormone therapies, and targeted cancer treatments. The goal is to see if these combinations can help people with cancers including ovarian, breast, prostate, and stomach cancer.
Many advanced cancers become resistant to single treatments, so researchers are exploring whether combining this new medication with existing cancer drugs could be more effective. This early-stage trial is designed to figure out the safest and most effective way to give this treatment before testing it in larger patient populations.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth daily as an outpatient, combined with one of several standard cancer drugs depending on your cancer type. You would visit the clinic regularly for the first several cycles (every 2–3 weeks) for blood tests, scans, and doctor visits to check how you're responding and monitor for side effects. After the initial phase, visits would become less frequent (every 6 weeks), and the study team would follow up with you for up to a year after your last dose to track your overall health and survival.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China